A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Biological Evaluation of Molecular Spherical Nucleic Acids: Targeting Tumors via a Hybridization-Based Folate Decoration
Tekijät: Auchynnikava, Tatsiana; Äärelä, Antti; Moisio, Olli; Liljenbäck, Heidi; Andriana, Putri; Iqbal, Imran; Laine, Toni; Palani, Senthil; Lehtimäki, Jyrki; Rajander, Johan; Salo, Harri; Airaksinen, Anu J.; Virta, Pasi; Roivainen, Anne
Kustantaja: American Chemical Society (ACS)
Julkaisuvuosi: 2025
Journal: ACS Omega
Tietokannassa oleva lehden nimi: ACS Omega
Vuosikerta: 10
Numero: 6
Aloitussivu: 6003
Lopetussivu: 6014
eISSN: 2470-1343
DOI: https://doi.org/10.1021/acsomega.4c10047
Verkko-osoite: https://doi.org/10.1021/acsomega.4c10047
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/485203712
Folate receptors (FRs), membrane-bound proteins that bind specifically to folate with high affinity, are overexpressed by various cancer types and are therefore used as targets for delivery of therapeutic agents. Molecular spherical nucleic acids (MSNAs) are dendritic formulations of oligonucleotides (ONs) that may have advantages over linear parent ONs with respect to delivery properties. Here, we assembled folate-decorated MSNAs, site-specifically radiolabeled them, and then biologically evaluated their effects in mice bearing HCC1954 breast cancer xenograft tumors. The biodistribution of intravenously administered 18F-radiolabeled MSNAs was monitored using positron emission tomography/computed tomography imaging. The results revealed higher accumulation of folate-decorated MSNAs in FR-expressing organs such as the liver, kidney, and spleen, as well as a higher tumor-to-muscle ratio than that observed for MSNAs without the folate decoration. However, the observed increase was statistically significant only for MSNA structures with a PO backbone. The observed selective uptake of folate-decorated MSNAs highlights their potential as targeted delivery vehicles for therapeutic and diagnostic agents in FR-overexpressing cancers.
Ladattava julkaisu This is an electronic reprint of the original article. |
Julkaisussa olevat rahoitustiedot:
This research was supported by the Research Council of Finland (decision numbers 3089312, 343608, and 350117), Business Finland Ecosystem Project (448/31/2018), University of Turku Drug Research Doctoral Program, Turku University Foundation, and the Jane and Aatos Erkko Foundation.